Lamivudin/Zidovudin Hexal (Zidovudine, Lamivudine)

Lamivudin/Zidovudin Hexal is a nucleoside reverse transcriptase inhibitor used effectively in the management of HIV infection worldwide.

• HIV‑1 infection (adults): Provides viral load reduction as part of combination antiretroviral therapy, improving immune function and disease outcomes.
• HIV‑1 infection (children): Contributes to viral suppression in pediatric patients when combined with other antiretrovirals, supporting growth and development.
• Prevention of mother‑to‑child transmission: Used in pregnant women to lower the risk of HIV transmission to the infant when part of a prescribed regimen.

• Lamivudine and zidovudine act as nucleoside analogues that are phosphorylated intracellularly and incorporated into viral DNA by HIV reverse transcriptase. Their incorporation terminates DNA chain elongation, thereby inhibiting viral replication and reducing HIV load in the patient.

Lamivudin/Zidovudin Hexal may cause several adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset, often transient.
• Headache: mild pain or pressure in the head.
• Fatigue: generalized tiredness, may affect daily activities.
• Anemia: reduced red blood cell count leading to pallor or weakness.

Serious or Rare Side Effects

• Severe lactic acidosis: accumulation of lactate causing metabolic disturbance, requires immediate medical attention.
• Hypersensitivity reaction: rash, fever, or organ involvement indicating an allergic response.
• Bone marrow suppression: significant drop in blood cell production, increasing infection or bleeding risk.

Before initiating Lamivudin/Zidovudin Hexal, clinicians should consider several precautionary measures to ensure patient safety.

• Monitor blood counts: Perform baseline and periodic CBC to detect anemia or neutropenia.
• Assess liver function: Check hepatic enzymes before and during therapy to identify potential toxicity.
• Avoid use in patients with known hypersensitivity: Discontinue immediately if allergic reactions occur.
• Consider renal function: Adjust dosing in severe renal impairment as per prescriber guidance.
• Pregnancy and breastfeeding: Use only if benefits outweigh potential risks to mother and infant.
• Store at ambient temperature: Keep below 25 °C, in original packaging, protect from moisture.

Lamivudin/Zidovudin Hexal can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

• Didanosine: Increased risk of pancreatitis when co‑administered.
• Stavudine: Enhanced mitochondrial toxicity leading to peripheral neuropathy.
• Alcohol: Exacerbates liver toxicity and may worsen hematologic side effects.

Moderate Interactions (Monitor Closely)

• Nevirapine: May raise plasma levels of lamivudine, requiring monitoring.
• Efavirenz: Can affect zidovudine metabolism, potentially altering drug concentrations.
• Rifampicin: Reduces plasma concentrations of both agents, possibly decreasing antiviral effectiveness.